AVAX Technologies, Inc. (AVXT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2007 | 7.31 Million USD | 17.27% |
| 2006 | 6.23 Million USD | 13.98% |
| 2005 | 5.46 Million USD | 8.69% |
| 2004 | 5.03 Million USD | 19.94% |
| 2003 | 4.19 Million USD | -58.73% |
| 2002 | 10.16 Million USD | 24.01% |
| 2001 | 8.19 Million USD | -37.13% |
| 2000 | 13.03 Million USD | 46.48% |
| 1999 | 8.9 Million USD | 30.88% |
| 1998 | 6.8 Million USD | 25.93% |
| 1997 | 5.4 Million USD | 145.45% |
| 1996 | 2.2 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2008 Q2 | 1.98 Million USD | -5.39% |
| 2008 Q1 | 2.09 Million USD | 0.06% |
| 2008 Q3 | 2.07 Million USD | 4.8% |
| 2007 FY | 7.31 Million USD | 17.27% |
| 2007 Q1 | 1.48 Million USD | -9.08% |
| 2007 Q2 | 1.66 Million USD | 12.44% |
| 2007 Q3 | 2.07 Million USD | 24.34% |
| 2007 Q4 | 2.09 Million USD | 1.17% |
| 2006 Q1 | 1.5 Million USD | -12.46% |
| 2006 Q3 | 1.49 Million USD | -6.06% |
| 2006 FY | 6.23 Million USD | 13.98% |
| 2006 Q4 | 1.62 Million USD | 8.59% |
| 2006 Q2 | 1.59 Million USD | 5.81% |
| 2005 Q3 | 979.09 Thousand USD | -35.43% |
| 2005 Q2 | 1.51 Million USD | 21.33% |
| 2005 FY | 5.46 Million USD | 8.69% |
| 2005 Q1 | 1.24 Million USD | -5.96% |
| 2005 Q4 | 1.72 Million USD | 76.03% |
| 2004 Q1 | 1.34 Million USD | 0.59% |
| 2004 Q4 | 1.32 Million USD | 15.37% |
| 2004 Q3 | 1.15 Million USD | -4.46% |
| 2004 Q2 | 1.2 Million USD | -10.33% |
| 2004 FY | 5.03 Million USD | 19.94% |
| 2003 Q1 | 1.34 Million USD | -81.46% |
| 2003 FY | 4.19 Million USD | -58.73% |
| 2003 Q3 | 1.15 Million USD | 217.04% |
| 2003 Q4 | 1.33 Million USD | 16.05% |
| 2003 Q2 | 363.31 Thousand USD | -72.95% |
| 2002 Q4 | 7.24 Million USD | 589.08% |
| 2002 FY | 10.16 Million USD | 24.01% |
| 2002 Q1 | 961.24 Thousand USD | -79.54% |
| 2002 Q3 | 1.05 Million USD | 16.14% |
| 2002 Q2 | 905.46 Thousand USD | -5.8% |
| 2001 Q4 | 4.69 Million USD | 380.22% |
| 2001 Q3 | 978.44 Thousand USD | 8.16% |
| 2001 Q2 | 904.62 Thousand USD | -43.98% |
| 2001 FY | 8.19 Million USD | -37.13% |
| 2001 Q1 | 1.61 Million USD | -47.68% |
| 2000 Q3 | 4.08 Million USD | 29.04% |
| 2000 Q4 | 3.08 Million USD | -24.44% |
| 2000 FY | 13.03 Million USD | 46.48% |
| 2000 Q2 | 3.16 Million USD | 17.31% |
| 2000 Q1 | 2.69 Million USD | -0.05% |
| 1999 Q2 | 2.1 Million USD | 10.53% |
| 1999 Q3 | 2.3 Million USD | 9.52% |
| 1999 Q1 | 1.9 Million USD | 11.76% |
| 1999 Q4 | 2.7 Million USD | 17.39% |
| 1999 FY | 8.9 Million USD | 30.88% |
| 1998 Q1 | 1.8 Million USD | 20.0% |
| 1998 FY | 6.8 Million USD | 25.93% |
| 1998 Q4 | 1.7 Million USD | 6.25% |
| 1998 Q3 | 1.6 Million USD | -11.11% |
| 1998 Q2 | 1.8 Million USD | 0.0% |
| 1997 Q2 | 1.4 Million USD | 7.69% |
| 1997 Q3 | 1.2 Million USD | -14.29% |
| 1997 FY | 5.4 Million USD | 145.45% |
| 1997 Q4 | 1.5 Million USD | 25.0% |
| 1997 Q1 | 1.3 Million USD | 0.0% |
| 1996 FY | 2.2 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -447.409% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -44.986% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 75.264% |
| Nascent Biotech, Inc. | 2.22 Million USD | -227.832% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1000.943% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 80.378% |
| Qrons Inc. | 643.67 Thousand USD | -1035.704% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1776.515% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 87.273% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1659.479% |
| Skye Bioscience, Inc. | 13.54 Million USD | 46.04% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 91.577% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -48.646% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -2693.098% |
| SQZ Biotechnologies Company | 85.61 Million USD | 91.462% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -150.675% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -386.735% |
| Mesoblast Limited | 5.9 Million USD | -23.861% |
| Marizyme, Inc. | 19.23 Million USD | 62.005% |
| Genus plc | 147.7 Million USD | 95.051% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 16.732% |
| Pharming Group N.V. | 225.49 Million USD | 96.758% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -256.824% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -444.914% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 12.336% |
| ContraFect Corporation | 56.88 Million USD | 87.15% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -65.816% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -394.354% |
| IMV Inc. | 37.7 Million USD | 80.614% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -161.983% |
| MultiCell Technologies, Inc. | 567.42 USD | -1288233.862% |
| ONE Bio Corp. | 6.44 Million USD | -13.445% |
| Accustem Sciences Inc. | 3.74 Million USD | -95.127% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 91.494% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1274.208% |
| Q BioMed Inc. | 3.43 Million USD | -112.716% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 70.422% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -178.219% |
| Biomind Labs Inc. | 994.18 Thousand USD | -635.304% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 92.64% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -315.432% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -8.816% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -292.104% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 29341.056% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 54.34% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -298.359% |
| GB Sciences, Inc. | 1.42 Million USD | -414.623% |
| Alpha Cognition Inc. | 9.7 Million USD | 24.68% |
| HST Global, Inc. | 140.9 Thousand USD | -5088.006% |
| CSL Limited | 3.44 Billion USD | 99.788% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -549.853% |
| Halberd Corporation | 74.84 Thousand USD | -9667.596% |
| Enzolytics Inc. | 2.17 Million USD | -235.409% |
| Agentix Corp. | 1.37 Million USD | -432.913% |
| Resverlogix Corp. | 12.71 Million USD | 42.493% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -100.242% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.523% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -600.217% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -203.969% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -362.864% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -114.693% |
| Zenith Capital Corp. | 8.94 Million USD | 18.257% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.114% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -41862.367% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -197.732% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -4162.321% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -280.563% |
| Kadimastem Ltd | 2.41 Million USD | -203.316% |
| Helix BioMedix, Inc. | 1.97 Million USD | -270.697% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 32.73% |
| BioStem Technologies, Inc. | 22.97 Million USD | 68.181% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -3928.027% |
| LadRx Corporation | 3.81 Million USD | -91.78% |
| Cell Source, Inc. | 4.32 Million USD | -69.01% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -691.574% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -691.574% |
| NovAccess Global Inc. | 2.46 Million USD | -196.351% |
| Affymax, Inc. | 39.38 Million USD | 81.439% |
| Itoco Inc. | 919.14 Thousand USD | -695.335% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -72.476% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -553.285% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1218.243% |
| CytoDyn Inc. | 18.05 Million USD | 59.518% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -28944.714% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -3221.67% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -414.883% |
| SYBLEU INC | 160.87 Thousand USD | -4444.036% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -302.477% |
| International Stem Cell Corporation | 5.27 Million USD | -38.688% |
| Bioxytran, Inc. | 3.82 Million USD | -91.361% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -13786.752% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -35835.034% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 79.843% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -351.809% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -893.465% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -134.981% |
| Neutra Corp. | 243.82 Thousand USD | -2898.209% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 58.124% |
| PureTech Health plc | 144.59 Million USD | 94.944% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 64.323% |
| IXICO plc | 4.7 Million USD | -55.306% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 16.9% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 93.792% |
| CSL Limited | 3.89 Billion USD | 99.812% |
| Cellectis S.A. | 97.32 Million USD | 92.488% |